不可切除胃癌的人表皮生长因子受体2表达与CT特征的关系
回顾性分析181例病理证实的不可切除胃癌(HER2阳性32例、阴性149例)的CT特征,发现HER2阳性者临床T分期更低、门脉期呈高强化、更常发生肝转移,肿瘤高强化(OR 4.68)和肝转移(OR 4.43)为独立预测因素,且HER2阳性者中位生存期更长(13.7个月 vs 9.6个月,p=0.035)。
要点
- HER2阳性胃癌门脉期高强化比例高于阴性者(62.5% vs 30.9%,p=0.003)。
- HER2阳性胃癌肝转移比例高于阴性者(62.5% vs 32.2%,p=0.001)。
- 肿瘤高强化(OR 4.68)和肝转移(OR 4.43)为HER2阳性的独立预测因素。
核心结论
- HER2阳性胃癌相比HER2阴性者表现为更低的T分期、门脉期高强化且更常发生肝转移,肿瘤高强化和肝转移是预测HER2阳性的独立因素。
研究设计与样本
- 回顾性分析181例病理证实的不可切除胃癌患者(HER2阳性32例、HER2阴性149例),复习原发胃肿瘤及转移瘤的CT特征,采用二元logistic回归确定差异CT特征,Kaplan-Meier法比较临床结局。
关键影像表现/征象
- HER2阳性胃癌门脉期呈高强化者占62.5%,HER2阴性者占30.9%(p=0.003)。
- HER2阳性胃癌肝转移者占62.5%,HER2阴性者占32.2%(p=0.001)。
- HER2阳性胃癌临床T分期较低者占21.9%,HER2阴性者占8.1%(p=0.015)。
诊断标准与关键数值
- 肿瘤高强化预测HER2阳性的OR为4.68(p<0.001)。
- 肝转移预测HER2阳性的OR为4.43(p=0.001)。
- HER2阳性者中位生存期13.7个月,HER2阴性者9.6个月(p=0.035)。
临床应用与阅片要点
- 阅片时门脉期肿瘤高强化和肝转移可提示HER2阳性可能,但原文未据此给出筛查或检测推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To retrospectively analyze the qualitative CT features that correlate with human epidermal growth factor receptor 2 (HER2)-expression in pathologically-proven gastric cancers.
MATERIALS AND METHODS: A total of 181 patients with pathologically-proven unresectable gastric cancers with HER2-expression (HER2-positive [n = 32] and negative [n = 149]) were included. CT features of primary gastric and metastatic tumors were reviewed. The prevalence of each CT finding was compared in both groups. Thereafter, binary logistic regression determined the most significant differential CT features. Clinical outcomes were compared using Kaplan-Meier method.
RESULTS: HER2-postive cancers showed lower clinical T stage (21.9% vs. 8.1%; p = 0.015), hyperattenuation on portal phase (62.5% vs. 30.9%; p = 0.003), and was more frequently metastasized to the liver (62.5% vs. 32.2%; p = 0.001), than HER2-negative cancers. On binary regression analysis, hyperattenuation of the tumor (odds ratio [OR], 4.68; p < 0.001) and hepatic metastasis (OR, 4.43; p = 0.001) were significant independent factors that predict HER2-positive cancers. Median survival of HER2-positive cancers (13.7 months) was significantly longer than HER2-negative cancers (9.6 months) (p = 0.035).
CONCLUSION: HER2-positive gastric cancers show less-advanced T stage, hyperattenuation on the portal phase, and frequently metastasize to the liver, as compared to HER2-negative cancers.
引用
- Lee JS, Kim SH, Im SA, et al. Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics. Korean J Radiol. 2017. PMID: 28860898. doi:10.3348/kjr.2017.18.5.809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。